medigraphic.com
ISSN 2305-7939 (Electronic)

2020, Number 3

<< Back Next >>

RCU 2020; 9 (3)

Oncological results of laparoscopic radical nephrectomy

González LT, Albelo AY, Sánchez TR, Morera PM, Quintana RM, Álvarez HS

Language: Spanish
References: 30
Page: 116-127
PDF size: 1020.50 Kb.


ABSTRACT

Introduction: Radical nephrectomy is the surgery of choice for cT1 or cT2 tumors whenever nephronsparing surgery is not possible and for those which are locally advanced. Laparoscopic radical nephrectomy is an alternative to open approach.
Objective: To describe oncological results of LRN in a series of patients.
Material and Method: A descriptive, retrospective study of 77 patients with a renal parenchymal tumor operated by LRN between 2006 and 2016 at the National Center for Minimally Invasive Surgery. To estimate survival, the Kaplan-Meier method was utilized and to analyze the difference in survival according to tumoral stage, the Log Rank, Breslow and Tarone-Ware method were used considering p < 0.05.
Results: Average age: 55.3 years. Males prevailed. 89.6 % had a malignant tumor and 77.9 % a clear cells renal carcinoma. 64.9 % were pT1N0M0. Cancer-specific and global mortality was 5.7 % and 7.7 %, respectively. There was one local recurrence and 7.5 % developed metastasis. 5 and 10 years survival rate was 90 %, and 92.5 %, 93.2 % and 50 % for pT1, pT2 y pT3 tumors, respectively, but this difference was not significant (p > 0.005).
Conclusions: LRN had satisfactory oncological results compared to those reported by international literature. Stage pT1 patients had better survival but the study did not achieve to demonstrate significant statistical differences in survival regarding tumoral stage.


REFERENCES

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015; 136(5): E359–86. DOI: https://doi.org/10.1002/ijc.29210

  2. León TG, Pérez MM. Renal cancer in the elderly. Curr Urol Rep. 2016; 17:6. DOI: https://doi:10.1007/s11934-015-0562

  3. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA Cancer J Clin. 2016; 66: 7-30. DOI: https://doi.org/10.3322/caac.21551

  4. Eltahawy E, Kamel M, Ezzet M. Management of renal cell carcinoma presenting as inflammatory renal mass. Urol Ann. 2015; [acceso: 26/04/20]; 7(3): 330-33. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PM C4518369/

  5. Motzer RJ, Jonasch E, Michaelson MD, Nandagopal L, Gore JL, George S, et al. NCCN guidelines insights: kidney cancer, version 2.2020. J Natl Compr Cancer Netw. 2019 [acceso: 26/04/20]; 17(11):1278. Disponible en: https://jnccn.org/view/journals/jnccn/17/11/ar ticle-p1278.xml

  6. Kunath F, Schmidt S, Krabbe LM, Miernik A, Dahm P, Cleves A, Walther M, Kroeger N. Partial nephrectomy versus radical nephrectomy for clinical localised renal masses. Cochrane Database Syst Rev. 2017 [acceso: 26/03/20]; 9:5(5). Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PM C6481491/

  7. Poletajew S, Antoniewicz AA, Borówka A. Kidney removal the past, presence, and perspectives a historical review. Urol J. 2010 [acceso: 22/04/20]; 7(4):215-23. Disponible en: https://journals.sbmu.ac.ir/urolj/index.php/uj/ article/view/814/502

  8. Liatsikos E, Kallidonis P, Do M, Dietel A, Al- Aown A, Constantinidis C, et al. Laparoscopic radical and partial nephrectomy: technical issues and outcome. World J Urol. 2013; 31(4): 785-91. DOI: https://doi.org/10.1007/s00345-011-0754- 4

  9. Gallardo E, Méndez-Vidal MJ, Pérez-Gracia JL, Sepúlveda-Sánchez J M, Campayo M, Chirivella- González I et al. SEOM clinical guideline for treatment of kidney cancer (2017). Clin Transl Oncol. 2018 [acceso: 26/03/20]; 20:47-56. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29134564/

  10. Häggström C, Rapp K, Stocks T, Manjer J, Bjørge, T, Ulmer H, et al. Metabolic factors associated with risk of renal cell carcinoma. PLoS ONE. 2013 [acceso: 26/04/20]; 8(2): e57475. Disponible en: https://pubmed.ncbi.nlm.nih.gov/23468995/

  11. Ridge C, Pua B, Madoff D. Epidemiology and staging of renal cell carcinoma. Semin Intervent Radiol. 2014 [acceso: 20/04/20]; 31(1):3-8. Disponible en: https://pubmed.ncbi.nlm.nih.gov/24596434/

  12. Escudier B, Porta C, Schmidinger M, Rioux- Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 [acceso: 16/04/20]; 27 (5):v58-v68, Disponible en: https://pubmed.ncbi.nlm.nih.gov/27664262/

  13. Reinstatler L, Klaassen Z, Barrett B, Terris MK, Moses KA. Body mass index and comorbidity are associated with postoperative renal function after nephrectomy. Int Braz J Urol. 2015 [acceso: 26/04/20]; 41(4):697-704. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26401862/

  14. Bamias A, Escudier B, Sternberg CN, Zagouri F, Dellis A, Djavan B. Current clinical practice guidelines for the treatment of renal cell carcinoma: a systematic review and critical evaluation. Oncologist. 2017 [acceso: 23/04/20]; 22(6): 667-79. Epub 2017 Jun 7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28592625/

  15. Guo J, Ma J, Sun Y, Qin S, Ye D, Zhou F et al. Chinese guidelines on the management of renal cell carcinoma (2015 edition). Ann Transl Med. 2015 [acceso: 26/04/20]; 3(19):279. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26932436/

  16. Janssen MWW, Linxweiler J, Terwey S, Rugge S, Ohlmann C-H, Becker F, et al. Survival outcomes in patients with large (>7cm) clear cell renal cell carcinomas treated with nephronsparing surgery versus radical nephrectomy: Results of a multicenter cohort with long-term follow-up. PLoS ONE. 2018 [acceso: 12/04/20]; 13(5):e0196427. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29723225/

  17. González León T, Suárez Marcillán ME, l García Morales I, Tegegne A, Hernández Castro JL, Figueroa Bonilla SG et al. Tumor de Wilms en el adulto. Rev Cubana Urol. 2015 [acceso: 29/04/20]; 4(1). Disponible en: http://www.revurologia.sld.cu/index.php/rcu/a rticle/view/230/235

  18. Moch H, Cubilla AL, Humphrey PA, Reuter V, Ulbright T, et al. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2016[acceso: 26/04/20]; 70: 93-105. Disponible en: https://pubmed.ncbi.nlm.nih.gov/26935559/

  19. Li G, Luo Q, Lang Z, Li Y, Wang A, Wang K, et al. Histopathologic analysis of stage pT1b kidney neoplasms for optimal surgical margins of nephron‑sparing surgery. Clin Transl Oncol. 2018 [acceso: 10/04/20]; 20:1196-1201. Disponible en: https://pubmed.ncbi.nlm.nih.gov/29564715/

  20. Liss M, DeConde R, Caovan D, Hofler J, Gabe M, Palazzi KL et al. Parenchymal volumetric assessment as a predictive tool to determine renal function benefit of nephron sparing surgery compared to radical nephrectomy. J Endouro. 2015 [acceso: 10/04/20]; 30(1). Disponible en: https://pubmed.ncbi.nlm.nih.gov/26192380/

  21. Yu-Li J, Cheng-Xia P, Heng-Zi W, Lu-Jie Q. Comparison of the long-term follow-up and perioperative outcomes of partial nephrectomy and radical nephrectomy for 4 cm to 7 cm renal cell carcinoma: a systematic review and metaanalysis. BMC Urology. 2019 [acceso: 13/04/20]; 19: 48. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31174522/

  22. Tan WS, Berg S, Cole AP, Krimphove M, Marchese M, Lipsitz SR et al. Comparing longterm outcomes following radical and partial nephrectomy for ct1 renal cell carcinoma in young and healthy individuals. JNCI Cancer Spectr. 2019 [acceso: 13/04/20]; 3(1): pkz003. Disponible en: https://pubmed.ncbi.nlm.nih.gov/31360891/

  23. Van Poppel H, Da Pozzo L, Albrecht W, Matveev V, Bono A, Borkowski A, et al. A prospective, randomised EORTC intergroup phase 3 study comparing the oncologic outcome of elective nephron-sparing surgery and radical nephrectomy for low-stage renal cell carcinoma. Eur Urol. 2011 [acceso: 10/04/20]; 59(4):543-52. Disponible en: https://pubmed.ncbi.nlm.nih.gov/21186077/

  24. An JY, Ball MW, Gorin MA, Hong JJ, Johnson MH, Pavlovich CP, et al. Partial vs radical nephrectomy for t1-t2 renal masses in the elderly: comparison of complications, renal function, and oncologic outcomes. Urology. 2017 [acceso: 12/04/20]; 100:151-7. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27889493/

  25. Jeong IG, Khandwala YS, Kim JH, et al. Association of robotic-assisted vs laparoscopic radical nephrectomy with perioperative outcomes and health care costs, 2003 to 2015. JAMA. 2017 [acceso: 9/04/20]; 318(16):1561-8. Disponible en https://pubmed.ncbi.nlm.nih.gov/29067427/

  26. Liu G, Ma Y, Wang S, Han X, Gao D. Laparoscopic versus open radical nephrectomy for renal cell carcinoma: a systematic review and meta-analysis. Transl Oncol. 2017 [acceso: 12/04/20]; 10(4):501-10. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28550770/

  27. Paparel P, Bigot P, Matillon X, Bensalah K, Salomon L, Baumert H, et al. Local recurrence after radical nephrectomy for kidney cancer: management and prediction of outcomes a multi-institutional study. J Surg Oncol. 2014 [acceso: 21/04/20]; 109(2):126-31. Disponible en: https://pubmed.ncbi.nlm.nih.gov/24174430/

  28. Zhang L, Wu B, Zha Z, Zhao H, Yuan J, Feng Y. The Correlation of clinicopathological features with the status of surgical margins in renal cell cancer patients following nephron-sparing surgery: A systematic review and meta-analysis. Front. Onco. 2019 [acceso: 21/04/20]; 9: 648. Disponible: https://scholar.google.com/scholar?cluster=30 26678729151339969

  29. Gong J, Maia MC, Dizman N, Govindarajan A, Pal SK. Metastasis in renal cell carcinoma: Biology and implications for therapy. Asian J Urol [acceso: 21/04/20]; 2016; 3(4):286-292. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PM C5730828/pdf/main.pdf

  30. Hemal AK, Kumar A, Kumar R, Wadhwa P, Seth A, Gupta NP, et al. Laparoscopic versus open radical nephrectomy for large renal tumors: A long-term prospective comparison. J Urol. 2007 [acceso: 21/04/20]; 177(3):862-6. Disponible en: https://pubmed.ncbi.nlm.nih.gov/17296361/




2020     |     www.medigraphic.com